Investigation of neoadjuvant chemohormonal therapy before robot-assisted radical prostatectomy for the patients with high-risk prostate cancer. - Neoadjuvant chemohormonal therapy for high-risk prostate cancer.

Takenaka Atsushi0 sites100 target enrollmentMarch 18, 2019

Overview

No summary available.

Registry

who.int

Start Date

March 18, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

Takenaka Atsushi

•1\) age \<\=75 years.
•2\) Prostate cancer patients who will be received RARP
•3\) Performance Status(PS:ECOG) 0\-1\.
•4\) Total bilirubin level less than 1\.5 times the upper limit of normal.
•AST/ALT(GOT/GPT) level less than 2\.5 times the upper limit of normal.
•Serum creatinine level less than 1\.5 times the upper limit of normal.
•Hgb level more than 8\.0g/dL, WBC level more than 3000/ul, Plt level more than 100,000/ul.
•5\) High risk patients with the total score more than 6 point.

•1\) Patient with the treatment history of docetaxel.
•2\) Patient with deep vein thrombosis.
•3\) Patient who has the past history of heart failure or myocardial infarction.
•4\) Patient with the past history of interstitial pneumonia.
•5\) An infectible patient.
•6\) Patient with diabetes with difficult control.
•7\) Patient who received medication of other investigational drugs within three months before the start of this study.
•8\) Patient who already received radiotherapy for prostate cancer.
•9\) Patient who is under treatment of other neoplasm except for the prostate cancer now.
•10\) Patient who is using the medicine with a possibility that blood concentration may rise by combined use.